Skip to main content

Table 2 A set of 61 GBM specimens for analyses of patient survival and the correlation between FABP7 and EGFR expression

From: Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma

Case #

Diagnosis

Age

Survival (wk)

Censor

FABP7 Nu

FABP7 Cyto

New Category*

EGFR IHC

P53 IHC

MIB-1

160

GBM

29

253

1

0

0

0

0

0

16.3

381

GBM

32

220

1

0

0

0

0

3

32.6

259

GBM

35

412

1

0

2

0

0

3

5.9

495

GBM

38

125

1

0

2

0

0

3

2.2

262

GBM

39

75.571

1

0

1

0

0

3

12.7

322

GBM

40

33.571

1

0

0

0

0

3

14.7

483

GBM

41

18.4286

1

0

1

0

0

1

6.2

499

GBM

43

26.143

1

0

0

1

2

1

10.8

198

GBM

43

83

1

0

1

0

0

3

32.7

310

GBM

43

66.143

1

0

2

0

0

0

33.6

307

GBM

44

65.4286

1

0

1

0

0

3

29.1

497

GBM

44

138.429

1

0

1

0

0

0

62.1

436

GBM

45

151.286

1

0

0

0

0

1

6.6

212

GBM

46

106.571

1

0

0

0

0

2

39.6

208

GBM

49

68.429

1

0

1

0

0

1

23.1

8

GBM

52

45.429

1

0

2

1

1

1

5.9

501

GBM

53

115.571

1

0

0

0

0

3

47.5

330

GBM

53

20.7143

1

0

1

0

0

2

36.5

446

GBM

56

41.571

1

0

0

0

0

3

39.2

404

GBM

56

68.857

1

0

2

0

0

3

36.1

288

GBM

57

38.2

1

0

0

1

1

2

21.8

19

GBM

58

80.429

1

0

2

0

0

3

6.1

292

GBM

58

38.2

1

0

2

NA

NA

0

NA

472

GBM

60

36.714

1

0

0

0

0

0

52.6

286

GBM

61

51.286

1

0

2

0

0

1

51.3

341

GBM

61

39.286

1

0

2

0

0

3

75.2

135

GBM

63

21.143

1

0

2

0

0

1

44.6

494

GBM

63

47.2

1

0

2

1

1

NA

NA

426

GBM

64

83.143

1

0

2

0

0

3

34.6

295

GBM

65

58.429

1

0

2

0

0

3

22.1

260

GBM

67

22.5

1

0

0

NA

NA

0

11.7

329

GBM

67

58.5

1

0

2

NA

NA

NA

NA

321

GBM

69

24.571

1

0

0

0

0

1

46.9

298

GBM

72

22.429

1

0

0

0

0

1

27.5

309

GBM

76

29.429

1

0

0

0

0

1

91.9

409

GBM

15

149.714

1

1

2

2

0

3

25.4

254

GBM

25

101.571

1

1

2

2

0

3

34.8

403

GBM

35

58

1

1

2

2

0

1

37.9

192

GBM

51

36

1

1

1

2

0

1

31.7

240

GBM

53

8.143

1

1

2

2

0

3

49.2

124

GBM

54

46.143

1

1

2

2

0

1

41.7

470

GBM

56

81

1

1

2

NA

NA

0

35.5

408

GBM

57

44

1

1

1

2

0

1

32.8

425

GBM

57

15.143

1

1

1

3

1

1

31.3

279

GBM

59

47.143

1

1

2

3

1

2

23.4

493

GBM

68

49.5

1

1

2

NA

NA

NA

NA

471

GBM

70

42.286

1

1

1

3

2

0

25.5

496

GBM

70

55.857

1

1

1

3

2

0

21.8

245

GBM

70

22.5

1

1

2

NA

NA

2

22

241

GBM

32

33.143

1

2

0

2

0

3

25.6

261

GBM

33

21.571

1

2

2

2

0

2

50.1

297

GBM

43

107.571

1

2

2

3

1

2

32.9

323

GBM

46

81

1

2

2

2

0

1

16.9

263

GBM

47

33.286

1

2

2

3

2

3

17.8

90

GBM

48

66.857

1

2

1

3

2

1

15.4

230

GBM

50

17.714

1

2

2

2

0

1

35.8

227

GBM

52

53.1429

1

2

2

3

1

1

43.1

325

GBM

52

32.143

1

2

2

3

2

0

20.3

443

GBM

55

59.286

1

2

1

3

2

1

39.7

296

GBM

59

39

1

2

0

2

0

1

44.9

335

GBM

75

18.143

1

2

2

2

0

1

27.5

  1. *Based on nuclear FABP7 and EGFR immunoreactivity: dual negative as "0", nuclear FABP7-/EGFR+ as "1", nuclear FABP7+/EGFR- as "2", and dual positive as "3"
  2. NA, no IHC data available.